We’re committed to reducing the transmission of genetic disease by providing solutions for preimplantation genetic diagnosis (PGD) of embryos. PGD helps patients prevent the transmission of inherited genetic disorders to children.
With multiple scientific publications from key leaders in the field, we’ve proven the strength and reliability of our technology. We are dedicated to providing both education and resources to improve patient access to embryo genetic screening.
Samples for embryo genetic screening are biopsied locally at the IVF clinic.
PGD is performed at a specialist genetic testing laboratory.
Couples do not need to travel to the testing site for chromosome screening, but can be kept informed by their chosen IVF clinic.
Illumina is committed to providing comprehensive solutions and to being a trusted partner to our customers across the reproductive health continuum. PGS and PGD solutions are at the forefront of this continuum and we aim to reshape the IVF process as we know it. With a world-class community of users, Illumina is a leader in the industry, driving the evolution of innovative applications of genetic technology in reproductive health.
From library prep, arrays, and sequencing to informatics, Illumina next-generation solutions empower researchers and clinicians across the globe to find the answers they seek.
We’re here with all the resources you need to accelerate progress. In addition to onsite training, ongoing support, and phone consults, we offer webinars and courses around the world.
Karyomapping is an advanced PGD technique for informed IVF embryo selection. Scientists in China used karyomapping to identify balanced translocation carriers and chromosomal abnormalities in blastocysts. They discuss the potential for this technique to limit IVF failure due to translocations.Read Interview